Commentary

JCP
The Long Road Toward Equitable MDMA Treatment in the United States
Commentary

May 29, 2024

Kozak and Aaronson discuss challenges in implementation of MDMA-assisted therapy, including insurance and Medicare coverage as well as cultural barriers.
,
JCP
Enhancing Postpartum Psychosis Care
Commentary

May 29, 2024

The authors discuss the need for qualitative research to fill gaps in the current understanding of postpartum psychosis, as well as the barriers that make conducting this research a...
, , , et al
JCP
How to Value a Life Without Limits: Quantifying Suffering With Quality-Adjusted Life Years in Social Anxiety Disorder
Commentary

May 27, 2024

The authors discuss a recent intriguing study published in JCP by Patel et al.
,
JCP
Psychosis, Inflammatory Biomarkers, and Subtypes of Childhood Trauma
Commentary

May 22, 2024

Dr Nasrallah discusses a recent study by Cuñat et al of the relationship between childhood trauma and inflammation, and why this work is unique and important.
JCP
Valproate and Weight Gain: A New Look at an Old Problem
Commentary

March 27, 2024

Dr Goldberg comments on a recent cohort study demonstrating a dose relationship with weight gain liability for valproate.
JCP
What Does a Systematic Review of Cannabis and PTSD Tell Us? That We Need to Learn More
Commentary

February 14, 2024

Dr Ostacher discusses a review by Rodas et al and points to a need for clear answers on how best to advise patients with PTSD and other psychiatric illness...
JCP
Enriching the Assessment of Suicidal Ideation
Commentary

January 17, 2024

The processes involved in the generation of suicidal ideation (SI) can be distinguished from those involved in the acts themselves. This commentary notes that the rise of digital health...
,
JCP
The Psychological Burden of ALS, the Enduring Strength of People Living With ALS, and the Tools We Can Use to Help
Commentary

December 13, 2023

Commenting on a recent article by Lester et al, the authors discuss the psychological impacts of diagnosis, genetic testing, and disease progression on patients with amyotrophic lateral sclerosis (ALS).
,
JCP
Long-Term Benzodiazepine Treatment: Toward Evidence-Based Practice Guidelines
Commentary

October 25, 2023

The evidence about long-term benzodiazepine use presents a confounding paradox. This commentary proposes a set of prescribing guidelines for clinicians.
, , , et al
JCP
COVID-19 Delirium and Motoric Subtypes: Improving Outcomes
Commentary

August 21, 2023

Randall T. Espinoza, MD, and Aaron Kaufman, MD, discuss a study by Trevisan et al and reflect on lessons learned during the pandemic about detecting and managing delirium.
,
JCP
The Potential Power of Virtual Group CBT
Commentary

July 24, 2023

Rachel Vanderkruik, PhD, MSc, discusses Huh and colleagues’ study of online nurse-delivered group CBT for postpartum depression, highlighting 4 key aspects that make the intervention particularly exciting.
JCP
Clinical Follow-Up and Widening LAI Intervals
Commentary

May 31, 2023

Although the administration intervals of long-acting injectable antipsychotics are a starting point for scheduling follow-ups, frequency of prescriber contact should be based on individual risk factors and real-world constraints.
, ,
JCP
rTMS for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies
Commentary

April 26, 2023

The authors argue that insurance companies’ prior authorization process overly restricts access to rTMS, which has proven effectiveness for TRD.
, , , et al
JCP
The Emerging Treatment Landscape in Schizophrenia
Commentary

January 18, 2023

This article provides an overview of emerging therapies poised to transform the treatment paradigm for patients with living with schizophrenia.
,
JCP
Schizophrenia: Salient Symptoms and Pathophysiology
Commentary

January 18, 2023

This article notes the distinction between positive and negative schizophrenic symptoms and provides an updated overview of disease pathophysiology.
JCP
Adverse Events and Treatment Adherence in Schizophrenia
Commentary

January 18, 2023

This article examines the effects of treatment-related adverse events on adherence to medication and strategies to improve adherence in practice.
,
JCP
The Epidemiology and Global Burden of Schizophrenia
Commentary

January 18, 2023

This article explores the costs and burden of schizophrenia and provides an overview of disease prevalence, incidence, and trends over time.
,
JCP
Optimizing Therapy Selection, Sequencing in Schizophrenia
Commentary

January 18, 2023

This article summarizes the current treatment landscape in schizophrenia, along with contexts in which agents should be prescribed.
,
JCP
Defining and Achieving Treatment Recovery in Schizophrenia
Commentary

January 18, 2023

This article defines treatment recovery in schizophrenia and summarizes strategies clinicians can pursue to improve patient outcomes.
,
JCP
Actualizing and Sustaining Recovery-Oriented Care
Commentary

January 16, 2023

Jack Tsai, PhD, comments on intensity of therapy and scalability issues in a recent study of the Opening Doors to Recovery program for SMI.
JCP
Recent Advances in Screening for Mild Cognitive Impairment and Alzheimer Disease
Commentary

December 26, 2022

Among the most transformative Alzheimer disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.
,
JCP
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease
Commentary

December 26, 2022

Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.
,
JCP
Developing Mental Illness Stigma–Reducing Interventions
Commentary

December 19, 2022

Research on antistigma interventions needs to look at sustained changes in attitudes and knowledge over time.
PCC
An Update on the Future of Wilson Disease Management
Commentary

November 29, 2022

Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen...

Watch the New PsychCase360

Explore two real-world schizophrenia cases
Promotional banner for a video titled “Choosing the Right LAI for Patients With Schizophrenia” featuring headshots of Roueen Rafeyan, MD, and Melissa Vitale, PMHNP, with a “Watch Now” button.

Subscribe to read
more articles

Subscribe